Published in Drug Week, March 30th, 2007
Vasostatin-Apo2L is a recombinant fusion protein with the potential to inhibit tumor growth. The treatment may integrate the function of an extracted fragment of Vasostatin, an inhibitor of angiogenesis and tumor growth with similar results of Rh-Apo2L, the Company's existing anti-cancer treatment currently in Phase II trials, which induces the apoptosis (cellular death) of cancer cells. Scientists from...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week